RT Journal Article
SR Electronic
T1 Globally altered epigenetic landscape and lagging osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.26.20089888
DO 10.1101/2020.05.26.20089888
A1 Pavlo Lutsik
A1 Annika Baude
A1 Daniela Mancarella
A1 Simin Öz
A1 Alexander Kühn
A1 Reka Toth
A1 Joschka Hey
A1 Umut H. Toprak
A1 Jinyeong Lim
A1 Viet Ha Nguyen
A1 Chao Jiang
A1 Anand Mayakonda
A1 Mark Hartmann
A1 Felix Rosemann
A1 Kersten Breuer
A1 Dominik Vonficht
A1 Florian Grünschläger
A1 Suman Lee
A1 Maren Kirstin Schuhmacher
A1 Denis Kusevic
A1 Anna Jauch
A1 Dieter Weichenhan
A1 Jozef Zustin
A1 Matthias Schlesner
A1 Simon Haas
A1 Joo Hyun Park
A1 Yoon Jung Park
A1 Udo Oppermann
A1 Albert Jeltsch
A1 Florian Haller
A1 Jörg Fellenberg
A1 Anders M. Lindroth
A1 Christoph Plass
YR 2020
UL http://medrxiv.org/content/early/2020/05/27/2020.05.26.20089888.abstract
AB The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration. We show that in patient-derived stromal cells H3.3-G34W is incorporated into the chromatin and associates with massive epigenetic alterations on the DNA methylation, chromatin accessibility and histone modification level that can be partially recapitulated in an orthogonal cell line system by the introduction of H3.3-G34W. These epigenetic alterations affect mainly heterochromatic and bivalent regions and provide possible explanations for the genomic instability as well as the osteolytic phenotype of GCTB. The mutation occurs in differentiating mesenchymal stem cells and associates with an impaired osteogenic differentiation. We propose that the observed epigenetic alterations reflect distinct differentiation stages of H3.3 WT and H3.3 MUT stromal cells and add to H3.3-G34W associated changes.Important abbreviations H3.3-G34W, mutated histone variant; H3.3 MUT, stromal cells expressing H3.3-G34W; H3.3 WT, stromal cells expressing wildtype H3.3Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was in part supported by Funds from the Helmholtz Foundation (C.P.), the Korean National Cancer Center (Grant No. 1810050-1 to A.M.L.), the Korean National Research Fund (Grant No. 2017R1E1A1A01073670 to A.M.L.), Oxford NIHR BRC (U.O.), Arthritis Research UK (program grant 20522 to U.O.). P.L., A.B. are DKFZ Postdoctoral Fellows. P.L. was supported by the Hemlholtz Association AMPro Project (ZT00026). A.K., A.M.T., D.M. are fellows of the Helmholtz International Graduate School for Cancer Research, J.H. is fellow of the German-Israeli Helmholtz Graduate School, C.J. is a recipient of a PhD fellowship from the Royal Commission for the Exhibition 1851, China-Oxford Scholarship Fund and UCB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics comittee HeidedelbergAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw sequencing data from WGS, WGBS, ATAC-seq, ChIP-seq, RNA-seq and deep targeted resequencing were obtained from patient samples (therefore restricted) and are being uploaded to European Genome-Phenome Archive (EGA): EGA: EGAS00001003730. Processed sequencing data and microarray data are being uploaded to the ArrayExpress database (E-MTAB-7184). All presented results were obtained with the use of published and publicly available software tools introduced in the Methods section.